Commentary

More than two-thirds of the surgeons believe that SLNB is now the standard of care, although both the American College of Surgeons and the NSABP have current clinical trials addressing this question. However, there is considerable controversy about the role of SLNB in several groups of patients, including patients who have undergone neoadjuvant therapy and those with more than one lesion in the same breast.

Select publications

Haid A et al. Is sentinel lymph node biopsy reliable and indicated after preoperative chemotherapy in patients with breast carcinoma? Cancer 2001;92:1080-4. Abstract

Julian TB et al. Sentinel lymph node biopsy after neoadjuvant chemotherapy for breast cancer. Am J Surg 2001;182(4):407-10. Abstract

Klauber-DeMore N et al. Sentinel lymph node biopsy: Is it indicated in patients with high-risk ductal carcinoma-in-situ and ductal carcinoma-in-situ with microinvasion? Ann Surg Oncol 2000;7(9):636-42. Abstract

Return